CN105439974A - A preparing method of a lipase inhibitor - Google Patents
A preparing method of a lipase inhibitor Download PDFInfo
- Publication number
- CN105439974A CN105439974A CN201410429315.8A CN201410429315A CN105439974A CN 105439974 A CN105439974 A CN 105439974A CN 201410429315 A CN201410429315 A CN 201410429315A CN 105439974 A CN105439974 A CN 105439974A
- Authority
- CN
- China
- Prior art keywords
- formula
- compound
- obtains
- bromine
- methyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 0 CCCc1ccc(C2CC2)c(C(NC(C)IC=CCCCCCC*)=[U])c1 Chemical compound CCCc1ccc(C2CC2)c(C(NC(C)IC=CCCCCCC*)=[U])c1 0.000 description 1
- IIRCBKRJABIEJT-UHFFFAOYSA-N NCC1=CC(I)=CCC1N Chemical compound NCC1=CC(I)=CCC1N IIRCBKRJABIEJT-UHFFFAOYSA-N 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
The invention belongs to the technical field of medicines, and particularly relates to a preparing method of 2-(hexadecyloxy)-6-methyl-4H-3,1-benzoxazin-4-one that is a lipase inhibitor. An intermediate that is hexadecyl-2-halogen-5-methyl-benzoyl carbamate shown as a formula (II) is subjected to amide cyclization and rearrangement with N-acyl-2-halogenobenzene under catalysis of a catalyst to prepare 1-(2-halogenbenzyl)-1,3-dione. -NH in imide and halogen are subjected to dehydrohalogenation to form a lactam four-membered ring firstly, and then the benzoxazin-4-one structure is formed by a C-N rearrangement reaction. The method is characterized by high product purity, simple, feasible and safe processes and capability of meeting requirements of industrial production.
Description
Technical field
The invention belongs to medical art, particularly, the present invention relates to the preparation method of a kind of lipase inhibitor Cetilistat (hereafter with its common name west for his Cetilistat of department).
Background technology
Due to the develop rapidly of science, the improvement of material life condition and the unreasonable of dietary structure, obesity sickness rate rises year by year, and occurs rejuvenation situation.Whole world obesity patient has 1,200,000,000 at least at present, and increases with every speed of doubling for 5 years.Ratio that China adult human body weight is overweight about 20% ~ 30%, big city reaches 35% ~ 40%, and in past 10 years, in Students ' Obesity patient, schoolgirl rises to 7% from 3%, and boy student rises to 8% from 2%, and overweight number is then 3 ~ 4 times of fat number.
West is a kind of new gastrointestinal lipases inhibitor for department he (Cetilistat), this medicine is used for obesity (and simultaneously with hyperlipemia and diabetes, weight index >=25) its great advantage for the treatment of be do not act on neural system, do not affect other enzymic activitys GI, do not absorbed and namely do not entered blood, not depress appetite, without the need to dietary restriction.After medication can there is the phenomenon (floating on water volume oil droplet) of defecation band oil in 24h, namely gets rid of not digested fat.
WO00/40247 describes west for taking charge of his preparation method, adopts amino-5 tolyl acids of 2-and chloroformic acid n-Hexadecane ester to be prepared by single stage method or two step method.Single stage method obtains product by the two direct polycondensation and cyclization in excess pyridine.In this method, 2-amino-5-tolyl acid cost of material costly; Chloroformic acid n-Hexadecane ester not only as reactant but also as the catalyzer of cyclization, but due to the activity of hexadecyl ester poor, catalytic capability is weak, and therefore yield is on the low side only has about 15%, and needs column chromatography purification; The methyl-chloroformate adopted in two step method is as the catalyzer of cyclization, and total recovery only has 31%.Adopt pyridine as solvent and acid binding agent in patent, consumption is large, expensive can not be reclaimed, and foul smelling has larger infringement to operator.
CN1785967 adopts hexadecyl-4-methyl phenyl carbamate through bromination, Carboxylation, obtains 2-n-Hexadecane oxygen base carbonylamino-5-tolyl acid, then in pyridine, reacts preparing product with Vinyl chloroformate.The method step is long, complicated operation, has and uses the operation such as bromine, high-pressure catalytic reaction, be unfavorable for industrial production in technique.
Summary of the invention
The object of the invention is to, provide a kind of west for the preparation method of his improvement of department.Method of the present invention has high, the simple for process and safety of product purity, is applicable to the feature of industrialization production requirements.
Technical scheme provided by the invention is as follows:
The present invention is by intermediate hexadecyl-2-halo-5-methyl-benzOylamino manthanoate formula II; under catalyst action; 1-(2-halogenophenyl)-1 is prepared by the cyclization-rearrangement reaction of N-acyl group-2-halogeno-benzene acid amides; 3-diketone; first form lactan tetra-atomic ring by-NH in imide with halogen dehydrohalogenation, then form benzoxazine-4-ketone structure through C-N rearrangement reaction.
Mantoquita catalyzed coupling reaction can generate C-C easily, the keys such as C-N, C-O, C-S, obtains a very large progress especially in recent years in Ullmann reaction.As Acc.Chem.Res, 2008,4 (11): 1450 methods reporting synthesizing benzimidazole under mantoquita catalyst system.The present invention adopts cuprous halide catalyzer to comprise cuprous chloride, cuprous bromide, cuprous iodide etc.
The certain acid binding agent of the reaction needed that the present invention relates to is for removing the hydrogen halide taken off, because highly basic can produce destruction to ester group, therefore acid binding agent uses inorganic weak bases, as salt of wormwood, sodium carbonate, potassiumphosphate, sodium phosphate, Potassium ethanoate, sodium-acetate etc., cesium carbonate.
In addition, adding some neutral salt can produce beyond thought effect to reaction, and reaction yield significantly improves.Described be neutral salt as magnesium oxide, calcium oxide, calcium chloride, magnesium sulfate, calcium sulfate etc. may be play part effect in the reaction, are conducive to reaction and carry out.
The method relates to new compound intermediate, hexadecyl-2-halo-5-methyl-benzOylamino manthanoate formula II, and this compound is prepared by following methods:
Method 1:
Halobenzamides (III) ,-NH
2the compound that group and phosgene or original position produce phosgene or comprise phosgene reacts and changes isocyanic ester (IV) into, then reacts with cetyl alcohol and prepares formula II.
X is substituted by halogen, comprises bromine and iodine.
React with acid amides that to prepare isocyanate reagents be that phosgene or original position produce phosgene or comprise the compound of phosgene, comprise phosgene, trichloromethylchloroformate, triphosgene and oxalyl chloride etc.
Method 2:
Halogeno-benzene ethamine (V) amido and chloroformic acid n-Hexadecane ester react prepares formula VI, and then formula II is prepared in oxidation.
X is substituted by halogen, comprises bromine and iodine.
Method 3:
Acid amides directly and carbonic acid two palm ester or chloroformic acid n-Hexadecane ester react and prepare formula II.
X is substituted by halogen, comprises bromine and iodine.
Embodiment
Referring to specific embodiment, the present invention is described.It will be appreciated by those skilled in the art that these embodiments only for illustration of object of the present invention, its scope do not limited the present invention in any way.
embodiment 12-bromo-5-methyl-benzoyl based isocyanate
2-bromo-5-methyl-benzamide 21.3g (0.1mol), methylene dichloride 200mL joins in three-necked bottle, and 0 DEG C slowly drips oxalyl chloride 33.3mL (0.4mol), rises to room temperature reaction 1 hour, then back flow reaction 2 hours, to producing without gas.Reaction solution is cooled to room temperature, and concentrating under reduced pressure steams solvent, obtains isocyanic ester crude product, is directly used in next step reaction.
embodiment 2hexadecyl-2-bromo-5-methyl-benzOylamino manthanoate
2-bromo-5-methyl-benzoyl based isocyanate prepared by upper step joins in methylene dichloride 250mL, adds hexadecanol 24.2g (0.1mol), and room temperature drips triethylamine 18mL; room temperature reaction 3 hours; add water 100mL, layering, organic layer anhydrous sodium sulfate drying.Decompression steams solvent, obtains crude product and adds Ethyl acetate-cyclohexane crystallization, obtain white solid 39.6g, yield 82%.
1hNMR: δ=0.96ppm (t, 3H ,-CH
3), 1.26 ~ 1.44 (m, 26H ,-CH
2), 1.73 (m, 2H ,-CH
2), 2.35 (s, 3H, CH
3), 4.22 (t, 2H ,-CH
2), 7.20 (d, 1H, phenyl ring), 7.49 (dd, 1H, phenyl ring), 7.64 (d, 1H, phenyl ring), 9.98 (br, 1H, N-H) ESIm/zC
25h
40brNO
3[M+1] 483
embodiment 32-iodo-5-methyl-benzoyl based isocyanate
2-iodo-5-methyl-benzamide 52.0g (0.2mol) joins toluene solution 250ml, be warming up to 90 DEG C and slowly drip two (trichloromethyl) carbonic ether 29.7g (0.1mol) 200mL toluene solution, then 30mL triethylamine is added, then back flow reaction 2h.Reaction solution is cooled to room temperature, and decompression steams solvent, obtains isocyanic ester crude product, is directly used in next step reaction.
embodiment 4hexadecyl-2-iodo-5-methyl-benzOylamino manthanoate
2-iodo-5-methyl-benzoyl based isocyanate prepared by upper step joins in methylene dichloride 500mL, adds hexadecanol 48.4g (0.2mol), and room temperature drips triethylamine 36mL; room temperature reaction 3 hours; add water 100mL, layering, organic layer anhydrous sodium sulfate drying.Decompression steams solvent, obtains crude product and adds Ethyl acetate-cyclohexane crystallization, obtain white solid 80.6g, yield 76%.
1hNMR: δ=0.95ppm (t, 3H ,-CH
3), 1.26 ~ 1.44 (m, 26H ,-CH
2), 1.72 (m, 2H ,-CH
2), 2.33 (s, 3H, CH
3), 4.22 (t, 2H ,-CH
2), 7.08 (d, 1H, phenyl ring), 7.52 (dd, 1H, phenyl ring), 7.70 (d, 1H, phenyl ring), 9.97 (br, 1H, N-H) ESIm/zC
25h
40iNO
3[M+1] 530
embodimentthe bromo-5-methylbenzylcarbamate of 5 hexadecyl-2-
2-bromo-5-methyl-benzyl amine 40g (0.2mol), methylene dichloride 500ml, add triethylamine 86ml (0.6mol), cool 0 DEG C, drip chloroformic acid n-Hexadecane ester 45.8g (0.15mol), be warming up to room temperature, room temperature reaction 3 hours, add water 200mL, layering, organic layer anhydrous sodium sulfate drying.Decompression steams solvent, obtains crude product and adds tetrahydrofuran (THF)-hexanaphthene crystallization, obtain white solid 82.5g, yield 88%.
1hNMR: δ=0.96ppm (t, 3H ,-CH
3), 1.29 ~ 1.45 (m, 26H ,-CH
2), 1.76 (m, 2H ,-CH
2), 2.36 (s, 3H, CH
3), 4.10 (t, 2H ,-CH
2), 4.25 (s, 2H ,-CH
2), 6.75 (d, 1H, phenyl ring), 6.76 (dd, 1H, phenyl ring), 7.19 (d, 1H, phenyl ring), 8.02 (, 1H, N-H) and ESIm/zC
25h
42brNO
2[M+1] 469
embodiment6 hexadecyl-2-bromo-5-methyl-benzOylamino manthanoate
Periodic acid 69g (0.3mol) and CrO
30.25g (5mol%) acetonitrile 500ml stirring at room temperature 30min, then diacetyl oxide 31g (0.3mol) is added, cool 0 DEG C, add the bromo-5 – methylbenzylcarbamate 23.4g (0.05mol) of hexadecyl-2-, mixture reaction 2h, add water 500ml, ethyl acetate 2L extracts, layering, saturated sodium carbonate solution and saturated sodium thiosulfate solution washing, dry, decompression steams solvent, add tetrahydrofuran (THF)-normal heptane recrystallization, obtain white solid 21.8g, yield 90%.ESIm/zC
25H
40BrNO
3[M+1]483
embodimentthe iodo-5-methylbenzylcarbamate of 7 hexadecyl-2 –
2-iodo-5-methyl-benzyl amine 49.4g (0.2mol), methylene dichloride 500ml, add triethylamine 86ml (0.6mol), cool 0 DEG C, drip chloroformic acid n-Hexadecane ester 45.8g (0.15mol), be warming up to room temperature, room temperature reaction 3 hours, add water 200mL, layering, organic layer anhydrous sodium sulfate drying.Decompression steams solvent, obtains crude product and adds tetrahydrofuran (THF)-hexanaphthene crystallization, obtain white solid 91.8g, yield 89%.
1hNMR: δ=0.96ppm (t, 3H ,-CH
3), 1.29 ~ 1.45 (m, 26H ,-CH
2), 1.76 (m, 2H ,-CH
2), 2.36 (s, 3H, CH
3), 4.10 (t, 2H ,-CH
2), 4.25 (s, 2H ,-CH
2), 6.75 (d, 1H, phenyl ring), 6.76 (dd, 1H, phenyl ring), 7.19 (d, 1H, phenyl ring), 8.02 (, 1H, N-H) and ESIm/zC
25h
42iNO
2[M+1] 516
embodiment 8hexadecyl-2-iodo-5-methyl-benzOylamino manthanoate
Periodic acid 69g (0.3mol) and CrO
30.25g (5mol%) acetonitrile 500ml stirring at room temperature 30min, then diacetyl oxide 31g (0.3mol) is added, cool 0 DEG C, add the iodo-5 – methylbenzylcarbamate 25.8g (0.05mol) of hexadecyl-2 –, mixture reaction 2h, add water 500ml, ethyl acetate 2L extracts, layering, saturated sodium carbonate solution and saturated sodium thiosulfate solution washing, dry, decompression steams solvent, add tetrahydrofuran (THF)-normal heptane recrystallization, obtain white solid 24.1g, yield 91%.ESIm/zC
25H
40INO
3[M+1]530
embodiment 9carbonic acid two palm ester
By palmityl alcohol 72.6g (0.3mol), catalyzer salt of wormwood 0.8g, joins in reaction flask, passes into nitrogen, is warming up to 160 DEG C, drips methylcarbonate 8.5ml (0.1mol), finishes and keeps this thermotonus 4h.The azeotrope collecting methyl alcohol and product carries out rectifying, obtains carbonic acid two palm ester 31.6g, yield 62%.
1hNMR: δ=0.85 (t, 6H, CH
3), 1.18-1.76 (m, 56H, CH
2), 4.22 (t, 4H, CH
2), C
33h
66o
3calculated value C77.58%, H13.02%; Measured value C77.31%, H13.31%.
embodiment 10hexadecyl-2-bromo-5-methyl-benzOylamino manthanoate
2-bromo-5-methyl-benzamide 21.3g (0.1mol), DMAP 14.6g (0.12mol), methylene dichloride 800mL joins in three-necked bottle, adds carbonic acid two palm ester 24.5g (0.048mol) in batches, room temperature reaction 18 hours.Reaction terminates, and saturated sodium bicarbonate is washed, washing and drying, and decompression steams solvent, obtains oily matter.Add tetrahydrofuran (THF)-normal heptane recrystallization, obtain white solid 32.8g, yield 67.9%.
1hNMR: δ=0.96ppm (t, 3H ,-CH
3), 1.26 ~ 1.44 (m, 26H ,-CH
2), 1.73 (m, 2H ,-CH
2), 2.35 (s, 3H, CH
3), 4.22 (t, 2H ,-CH
2), 7.20 (d, 1H, phenyl ring), 7.49 (dd, 1H, phenyl ring), 7.64 (d, 1H, phenyl ring), 9.98 (br, 1H, N-H) ESIm/zC
25h
40brNO
3[M+1] 483
embodiment 11hexadecyl-2 – iodo-5-methyl-benzOylamino manthanoate
2-iodo-5-methyl-benzamide 26.0g (0.1mol), triethylamine 43ml (0.3mol), tetrahydrofuran (THF) 200mL joins in three-necked bottle, drips chloroformic acid n-Hexadecane ester 36.7g (0.12mol), room temperature reaction 2 hours, then back flow reaction 2 hours.Reaction terminates, and by reaction solution impouring 100ml water after cooling, separates out solid.Add tetrahydrofuran (THF)-normal heptane recrystallization, obtain white solid 30.7g, yield 58%.ESIm/zC
25H
40INO
3[M+1]530
embodiment 12for department, he prepares in west
Cuprous bromide 0.7g (5mmol); potassiumphosphate 2.12g (10mmol); magnesium sulfate 1.2g (10mmol) joins in dry toluene 500ml; after passing into nitrogen; add hexadecyl-2-bromo-5-methyl-benzOylamino manthanoate 24.2g (0.05mol) under stirring, be warming up to backflow 3h.Reaction terminates rear filtration, and filtrate reduced in volume obtains oily matter, adds normal heptane-ethyl alcohol recrystallization, obtains off-white color solid 14.2g, yield 71%.ESIm/zC
25h
39nO
3[M+1] 402
1hNMR: δ=0.86ppm (t, 3H ,-CH
3), 1.24 ~ 1.44 (m, 26H ,-CH
2), 1.79 (m, 2H ,-CH
2), 2.40 (s, 3H, CH
3), 4.40 (t, 2H ,-CH
2), 7.28 (d, 1H, phenyl ring), 7.50 (dd, 1H, phenyl ring) 7.88 (d, 1H, phenyl ring), HPLC99.87%
embodiment 13for department, he prepares in west
Cuprous iodide 1g (5mmol); potassiumphosphate 2.12g (10mmol); calcium chloride 1.11g (10mmol) joins in dioxane 500ml; after passing into nitrogen; add hexadecyl-2-iodo-5-methyl-benzOylamino manthanoate 26.6g (0.05mol) under stirring, be warming up to backflow 3h.Reaction terminates rear filtration, and filtrate reduced in volume obtains oily matter, adds normal heptane-ethyl alcohol recrystallization, obtains off-white color solid 16.2g, yield 81%.ESIm/zC
25h
39nO
3[M+1] 402
1hNMR: δ=0.86ppm (t, 3H ,-CH
3), 1.24 ~ 1.44 (m, 26H ,-CH
2), 1.79 (m, 2H ,-CH
2), 2.40 (s, 3H, CH
3), 4.40 (t, 2H ,-CH
2), 7.28 (d, 1H, phenyl ring), 7.50 (dd, 1H, phenyl ring) 7.88 (d, 1H, phenyl ring), HPLC99.85%.
Claims (7)
1. prepare a method for compound shown in formula I, it is characterized in that, obtained by formula II compound,
Wherein X is bromine or iodine.
2. preparation method according to claim 1, is characterized in that, adopts cuprous halide as catalyzer, is selected from cuprous chloride, cuprous bromide, cuprous iodide.
3. method according to claim 1, is characterized in that, adopts weak base as acid binding agent, is selected from salt of wormwood, sodium carbonate, potassiumphosphate, sodium phosphate, Potassium ethanoate, sodium-acetate, cesium carbonate.
4. method according to claim 1, is characterized in that, adopts neutral salt as cocatalyst, is selected from magnesium oxide, calcium oxide, calcium chloride, magnesium sulfate, calcium sulfate.
5. method according to claim 1, formula II compound obtains by following steps:
Wherein X is bromine or iodine;
Formula III compound substituted benzamide and phosgene or original position produce phosgene or comprise the substance reaction of phosgene; The formula IV compound obtained and hexadecanol react, and obtain formula II compound.
6. method according to claim 1, formula II compound obtains by following steps:
Wherein X is bromine or iodine;
Formula (V) compound alpha substituted benzylamine and chloroformic acid n-Hexadecane ester react; The formula VI compound obtained obtains formula II compound through peroxidation.
7. method according to claim 1, formula II compound obtains by following steps:
Wherein X is bromine or iodine;
Formula (VII) compound substituted amide chloro-formic ester and chloroformic acid n-Hexadecane ester or carbonic acid two palm ester react, obtained formula II compound.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410429315.8A CN105439974B (en) | 2014-08-28 | 2014-08-28 | A kind of preparation method of lipase inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410429315.8A CN105439974B (en) | 2014-08-28 | 2014-08-28 | A kind of preparation method of lipase inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105439974A true CN105439974A (en) | 2016-03-30 |
| CN105439974B CN105439974B (en) | 2018-01-12 |
Family
ID=55550673
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410429315.8A Active CN105439974B (en) | 2014-08-28 | 2014-08-28 | A kind of preparation method of lipase inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105439974B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| CN1785967A (en) * | 2004-12-10 | 2006-06-14 | 兰爱克谢斯德国有限责任公司 | Process for the preparation of carbamic acid derivatives |
-
2014
- 2014-08-28 CN CN201410429315.8A patent/CN105439974B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5948775A (en) * | 1997-03-19 | 1999-09-07 | American Home Products Corporation | 2- or 3-(substitutedaminoalkoxyphenyl)quinazolin-4-ones |
| CN1785967A (en) * | 2004-12-10 | 2006-06-14 | 兰爱克谢斯德国有限责任公司 | Process for the preparation of carbamic acid derivatives |
Non-Patent Citations (3)
| Title |
|---|
| 杨义生: "一种新型减肥药物———奥利司他", 《国外医学内分泌学分册》 * |
| 杨志秋等: "脂肪酶抑制剂应用于抗肥胖的研究进展", 《现代生物医学进展》 * |
| 阎家麒等: "赛利司他(ATL -962)、利莫那班和赛尼可的研发与市场趋势", 《化工时刊》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105439974B (en) | 2018-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN114085181B (en) | Synthetic method and application of 6, 6-dimethyl-3-azabicyclo [3.1.0] hexane | |
| CA1168251A (en) | 1,3-dioxolen-2-one derivatives and process for production thereof | |
| CN103304547A (en) | Preparation method of antidepressant drug-vilazodone | |
| CN105254589B (en) | A method of preparing heart failure drugs intermediate | |
| CN109438432A (en) | A kind of preparation method of emtricitabine | |
| CN106365986A (en) | Compounds and preparation methods thereof, and uses of compounds in synthesis of brivaracetam | |
| CN101735134A (en) | Chiral 3-hydroxy pyrrolidone compound and preparation method and application thereof | |
| CN105439974A (en) | A preparing method of a lipase inhibitor | |
| CN103864615A (en) | Method for preparing ethyl trifluoroacetate through continuous non-catalytic method | |
| CN103724203A (en) | Preparation method of o-methyl hydroxyphenylacetate | |
| CN104710367A (en) | Method for synthesizing enzalutamide | |
| CN102002012A (en) | Method for synthesizing 1,3-oxazole-2,4-diketone compounds | |
| CN103408450A (en) | Method for catalytically synthesizing tamibarotene through acenaphthene imidazole n-heterocyclic carbine allyl palladium chloride compound | |
| CN102260213B (en) | Method for preparing tolvaptan | |
| CN101948455A (en) | Preparation method of 2-n-butyl-3-(4-hydroxybenzoyl)-5-nitrobenzofuran | |
| CN101348475A (en) | Novel method for synthesizing orlistat, intermediate compound and preparation thereof | |
| CN113773182A (en) | Method for synthesizing 6, 8-dichloro caprylic acid ester | |
| CN101328110A (en) | Preparation of butoconazole nitrate intermediate | |
| CN105646403B (en) | A kind of chemical synthesis process of the oxo octanoic acid methyl esters of 8 furans 8 | |
| CN102070633B (en) | Method for synthesizing 1,8-diazaspiro[4.5]decane with protective group | |
| CN107304171A (en) | A kind of synthetic method of Oseltamivir | |
| CN104693071A (en) | N-hydroxyl-N'-benzyl octanediamide preparation method | |
| CN104250267B (en) | The preparation method of tynofovir two pyrrole furan ester | |
| CN101948454A (en) | Method for preparing 2-butyl-5-nitrobenzofuran | |
| CN106220625B (en) | A kind of synthetic method of pirenzepine hydrochloride key intermediate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |